Ghrelin Decreases Insulin Sensitivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00512525
Recruitment Status : Completed
First Posted : August 7, 2007
Last Update Posted : September 9, 2009
Information provided by:
University of Aarhus

Brief Summary:
Ghrelin administration increases appetite and, in rodents, induces weight gain. The aim of this study is to investigate the effect of short term ghrelin administration to humans on metabolism.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Ghrelin and saline (as placebo) Phase 1

Detailed Description:
The current study is initiated in order to assess the impact of acute ghrelin administration on insulin resistance measured by a hyperinsulinemic euglycemic clamp. Second, as free fatty acid is the predominant substrate during fasting, we aim to asses the effects of ghrelin on local and systemic lipolysis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Health Services Research
Official Title: Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men
Study Start Date : January 2003
Actual Primary Completion Date : October 2003
Actual Study Completion Date : October 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
Drug Information available for: Insulin
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 2 Drug: Ghrelin and saline (as placebo)
Intravenous infusion

Primary Outcome Measures :
  1. Insulin sensitivity [ Time Frame: End of clamp period ]

Secondary Outcome Measures :
  1. Effects on lipolysis [ Time Frame: End of basal and end og clamp period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy men, age >= 18 yr age < 50 yr, body mass index < 27.5 kg/m2above or equal to 18 yr

Exclusion Criteria:

  • any disease, use of prescribed medication, age < 18 yr or >= 50 yr

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00512525

Sponsors and Collaborators
University of Aarhus
Study Director: Ole Schmitz, MD Department of Pharmacology, University of Aarhus, Denmark

Responsible Party: Esben T. Vestergaard, Aarhus University Hospital Identifier: NCT00512525     History of Changes
Other Study ID Numbers: ETV2007
First Posted: August 7, 2007    Key Record Dates
Last Update Posted: September 9, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs